The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Targeting T cells to treat atherosclerosis: odyssey from bench to bedside
Open accessAbstract
More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond, and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize recent advances on the role of CD4(+) T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, CD4+, CD28-null, CD45 re-expressing senescent T-cells (also known as CD4+ T-EMRA cells) were found to be highly active subpopulations, expressing increased amounts of TNF-α, INF-γ, CXCR-3 (C-X-C chemokine receptor), CCR-6, CCR-7 (C-C motif chemokine receptor 6 and 7), and the anti-apoptotic Bcl-2 family proteins.19,116”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredIn the citing paper
“Navitoclax, a Bcl-2 inhibitor, has beneficial effects in atherosclerosis,9 and may be a good candidate for the targeting of T-EMRA cells, which overexpress Bcl-2 family proteins.116”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · cited 4×
“suppressive function.(30,31) Regulatory T cells identified by this meth-”
BackgroundInfluentialFOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439 · cited 6×
“The most numerous and best-characterized are thymus-derived (naturally occurring) Treg (identified as CD4+CD25highCD127lowFOXP3+ T cells), as opposed to peripherally derived (induced) Treg, which originate from naive conventional T cells.(31) Regulatory T cells comprise around 5% of CD4+ T cells in the peripheral bloo…”
BackgroundInfluentialThe immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,317 · cited 3×
“tions of lipids, but sites of active interactions between cells of the immune system and vascular cells that influence the fate of atheromas.(1) As evidenced in several studies in animal models and patients,”
BackgroundInfluentialRequirement of bic/microRNA-155 for Normal Immune Function
Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., van Dongen, S., Grocock, R. J., Das, P. P., Miska, E. A., et al. (2007) · Science · doi:10.1126/science.1139253 · Cited by 1,833 · cited 1×
“MicroRNA-155 has also been implicated in the generation of Th1 cells, as T lymphocytes from miR-155 mice showed skewing towards Th2 with predominant production of IL-4 and IL-10 and deficient IFN-g secretion.(53) Interestingly, miR-155 was also implicated in Treg survival.”
BackgroundNatural regulatory T cells control the development of atherosclerosis in mice
Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,100 · cited 2×
“gression, although the mechanisms responsible remain poorly defined.(33) – 35 Data on Treg in human atherosclerosis are scant and fraught with contradictory findings.”
BackgroundLu, L.-F., Thai, T.-H., Calado, D. P., Chaudhry, A., Kubo, M., Tanaka, K., Loeb, G. B., Lee, H., Yoshimura, A., Rajewsky, K., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.010 · Cited by 783 · cited 1×
“Interestingly, miR-155 was also implicated in Treg survival.(54) MicroRNA-146a is upregulated in ACS and promotes Th1 differentiation through T-bet induction.”
BackgroundThe multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models
Weber, C., Zernecke, A., & Libby, P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2415 · Cited by 776 · cited 1×
“and have significant effects on the initiation and progression of atherosclerotic lesions.(2,3) Interactions between immune and vascu-”
BackgroundDetection of activated T lymphocytes in the human atherosclerotic plaque.
Hansson, G. K., Holm, J., & Jonasson, L. (1989) · Europe PMC (PubMed Central) · Cited by 744
Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans
Libby, P., Lichtman, A. H., & Hansson, G. K. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.009 · Cited by 671 · cited 3×
“and have significant effects on the initiation and progression of atherosclerotic lesions.(2,3) Interactions between immune and vascu-”
BackgroundMonoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., & Weyand, C. M. (2000) · Circulation · doi:10.1161/01.cir.101.25.2883 · Cited by 552
Research works printed but not linked: 1
- 10.1002/1529-0131(199812)41:12<2108::AID-ART5>3.0.CO;2-Q · DOI
Cited by
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
“motif chemokine receptor 6 and 7), and the anti-apoptotic Bcl-2 family proteins.(19,116) In addition to the pro-inflammatory phenotype,”
BackgroundMa, Q., Fan, Q., Han, X., Dong, Z., Xu, J., Bai, J., Tao, W., Sun, D., & Wang, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.064 · Cited by 112
Wang, H., Liu, Z., Shao, J., Lin, L., Jiang, M., Wang, L., Lu, X.-C., Zhang, H. S., Chen, Y., & Zhang, R. (2020) · Journal of Immunology Research · doi:10.1155/2020/4904217 · Cited by 130
Regulatory T cells as a new therapeutic target for atherosclerosis
Ou, H.-X., Guo, B.-B., Liu, Q., Li, Y., Yang, Z., Feng, W., & Mo, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.140 · Cited by 106
Notch Signaling Regulates Immune Responses in Atherosclerosis
Sega, F. V. D., Fortini, F., Aquila, G., Campo, G. C., Vaccarezza, M., & Rizzo, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01130 · Cited by 107
Metadata
- Authors
- Bullenkamp, J., Dinkla, S., Kaski, J. C., & Dumitriu, I. E.
- Affiliations
- St George's, University of London (GB)
- Corresponding author
- Dumitriu, Ingrid E.
- Venue
- European Heart Journal - Cardiovascular Pharmacotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-24
- Volume
- 2
- Issue
- 3
- Pages
- 194-199
- ISSN
- 2055-6837 (ISSN-L)
- 2055-6845
- PMC
- PMC4907356
- OpenAlex
- W2297695250
- Cited by
- 38
- References
- 60
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 5 · 2016: 3
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- European Heart Journal - Cardiovascular Pharmacotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- St George's Online Research Archive (St George's University of London) (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- British Heart Foundation (PG/10/50/28434, PG/13/24/30115, PG/14/18/30724)
- St George's Hospital Charity
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atherosclerosis, T cells, CD4+ T cells, inflammation, anti-inflammatory therapy, T cell subsets, macrophages, lymphocytes, atherosclerotic plaque, immunomodulation, clinical translation
- MeSH terms
- Animals, Humans, T-Lymphocytes, CD4-Positive T-Lymphocytes, Atherosclerosis, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. https://app.cochat.ai/papers/10.1093/ehjcvp/pvw001
- The paper
- Bullenkamp, J., Dinkla, S., Kaski, J. C., & Dumitriu, I. E. (2016). Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvw001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.